Prognostic variables in greek patients with stage II breast cancer: a Hellenic Cooperative Oncology Group study.
The independent effects of several patient, tumor and treatment-related prognostic factors on relapse-free survival (RFS) and overall survival (OS) were assessed by Cox multivariate regression analysis in 988 Greek patients with stage II breast cancer. At a median follow-up time of 83 (range 3.3-131+) months and after the evaluation of all patients together, the number of positive axillary nodes (p < 0.0001), tumor size (p = 0.0024) and tumor grade (p = 0.0008) were identified as significant prognostic factors for RFS. Also, the number of positive nodes (p < 0.0001), tumor size (p = 0.0002) and ER status (p = 0.0001) were found to be significant for OS. These short-term prognostic variables are similar to those reported for this group of patients in other European countries and in the USA.
Fountzilas
G
G
AHEPA Hospital, Aristotle University of Thessaloniki, Greece.
Vasilaros
S
S
Koukouras
D
D
Malamos
N
N
Pectasides
D
D
Adamou
A
A
Nenopoulou
E
E
Kiriakou
K
K
Zouvani
I
I
Katsohis
K
K
Kappas
A
A
Skopa
C
C
Semoglou
C
C
Fahantidis
E
E
Konstantaras
C
C
Vasilaki
E
E
Economopoulos
T
T
Bacoyiannis
H
H
Bafaloukos
D
D
Razi
E
E
Polichronis
A
A
Androulakis
G
G
Papaioannou
T
T
Pavlidis
N
N
Kosmidis
P
P
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000401:mortality / Q000473:pathology* / Q000601:surgery / Q000628:therapy*; D017024:Chemotherapy, Adjuvant; D003131:Combined Modality Therapy; D018572:Disease-Free Survival; D005060:Europe; D005260:Female; D006115:Greece; D006801:Humans; D008207:Lymphatic Metastasis; D008499:Medical Records; D008593:Menopause; D008875:Middle Aged; D015999:Multivariate Analysis; D009367:Neoplasm Staging; D011379:Prognosis; D011960:Receptors, Estrogen / Q000032:analysis; D012008:Recurrence; D012044:Regression Analysis; D012189:Retrospective Studies; D015996:Survival Rate; D013629:Tamoxifen / Q000627:therapeutic use; D014481:United States
D011960:Receptors, Estrogen; D013629:Tamoxifen